Company
Headquarters: Taipei, Taiwan
TW$15.34 Billion
TWD as of Jan. 1, 2024
US$499.9 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. It offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, and other forms. It also offers contract manufacturing services. The company also exports its products to South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua. Synmosa Biopharma Corporation was incorporated in 1980 and is based in Taipei City, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Synmosa Biopharma Corp has the following listings and related stock indices.
Stock: TWSE: 4114 wb_incandescent